REGENXBIO Share Holder Equity 2014-2022 | RGNX

REGENXBIO share holder equity from 2014 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
REGENXBIO Annual Share Holder Equity
(Millions of US $)
2021 $764
2020 $378
2019 $450
2018 $509
2017 $183
2016 $162
2015 $217
2014 $-6
2013 $-2
REGENXBIO Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $690
2021-12-31 $764
2021-09-30 $461
2021-06-30 $507
2021-03-31 $555
2020-12-31 $378
2020-09-30 $416
2020-06-30 $398
2020-03-31 $420
2019-12-31 $450
2019-09-30 $468
2019-06-30 $495
2019-03-31 $487
2018-12-31 $509
2018-09-30 $494
2018-06-30 $317
2018-03-31 $299
2017-12-31 $183
2017-09-30 $195
2017-06-30 $212
2017-03-31 $213
2016-12-31 $162
2016-09-30 $180
2016-06-30 $196
2016-03-31 $209
2015-12-31 $217
2015-09-30 $222
2015-06-30 $0
2015-03-31 $0
2014-12-31
2014-09-30 $0
2013-12-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.106B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00